No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...
As fears grow of a possible bird flu pandemic in humans, the federal government is pouring more money into the development of ...
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
Whilst vaccines exist for animals, none are commercially available for human use for the mosquito-borne virus.
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
CLAIM: HIV is part of the composition of COVID-19 vaccinesFACT: False. An experimental vaccine developed by Professor Keith ...
Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...
The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to ...